Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Urinary miRNA Profiles in Chronic Kidney Injury-Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial Dysfunction.
Petzuch B, Bénardeau A, Hofmeister L, Meyer J, Hartmann E, Pavkovic M, Mathar I, Sandner P, Ellinger-Ziegelbauer H. Petzuch B, et al. Among authors: benardeau a. Toxicol Sci. 2022 Apr 26;187(1):35-50. doi: 10.1093/toxsci/kfac028. Toxicol Sci. 2022. PMID: 35244176
Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.
Bénardeau A, Kahnert A, Schomber T, Meyer J, Pavkovic M, Kretschmer A, Lawrenz B, Hartmann E, Mathar I, Hueser J, Kraehling JR, Eitner F, Hahn MG, Stasch JP, Sandner P. Bénardeau A, et al. Naunyn Schmiedebergs Arch Pharmacol. 2021 Dec;394(12):2363-2379. doi: 10.1007/s00210-021-02149-4. Epub 2021 Sep 22. Naunyn Schmiedebergs Arch Pharmacol. 2021. PMID: 34550407 Free PMC article.
Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).
Hahn MG, Lampe T, El Sheikh S, Griebenow N, Woltering E, Schlemmer KH, Dietz L, Gerisch M, Wunder F, Becker-Pelster EM, Mondritzki T, Tinel H, Knorr A, Kern A, Lang D, Hueser J, Schomber T, Benardeau A, Eitner F, Truebel H, Mittendorf J, Kumar V, van den Akker F, Schaefer M, Geiss V, Sandner P, Stasch JP. Hahn MG, et al. Among authors: benardeau a. J Med Chem. 2021 May 13;64(9):5323-5344. doi: 10.1021/acs.jmedchem.0c02154. Epub 2021 Apr 19. J Med Chem. 2021. PMID: 33872507 Free article.
Role of soluble guanylyl cyclase in renal afferent and efferent arterioles.
Wennysia IC, Zhao L, Schomber T, Braun D, Golz S, Summer H, Benardeau A, Lai EY, Lichtenberger FB, Schubert R, Persson PB, Xu MZ, Patzak A. Wennysia IC, et al. Among authors: benardeau a. Am J Physiol Renal Physiol. 2021 Feb 1;320(2):F193-F202. doi: 10.1152/ajprenal.00272.2020. Epub 2020 Dec 28. Am J Physiol Renal Physiol. 2021. PMID: 33356952 Free article.
6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds.
Röver S, Andjelkovic M, Bénardeau A, Chaput E, Guba W, Hebeisen P, Mohr S, Nettekoven M, Obst U, Richter WF, Ullmer C, Waldmeier P, Wright MB. Röver S, et al. Among authors: benardeau a. J Med Chem. 2013 Dec 27;56(24):9874-96. doi: 10.1021/jm4010708. Epub 2013 Nov 20. J Med Chem. 2013. PMID: 24175572
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Alig L, Alsenz J, Andjelkovic M, Bendels S, Bénardeau A, Bleicher K, Bourson A, David-Pierson P, Guba W, Hildbrand S, Kube D, Lübbers T, Mayweg AV, Narquizian R, Neidhart W, Nettekoven M, Plancher JM, Rocha C, Rogers-Evans M, Röver S, Schneider G, Taylor S, Waldmeier P. Alig L, et al. Among authors: benardeau a. J Med Chem. 2008 Apr 10;51(7):2115-27. doi: 10.1021/jm701487t. Epub 2008 Mar 13. J Med Chem. 2008. PMID: 18335976
40 results